AGM/EGMJun 16, 2026, 04:47 PM
Silexion Therapeutics Calls EGM for Warrant Exercisability & Share Capital Increase
AI Summary
Silexion Therapeutics Corp. is holding an extraordinary general meeting on July 13, 2026, to seek shareholder approval for two key proposals. The first is the exercisability of new warrants and placement agent warrants issued in a May 18, 2026, transaction that helped restore Nasdaq listing compliance. The second proposal seeks to increase the authorized share capital by 10,000,000 ordinary shares to support ongoing operations, clinical trials for its SIL-204 product candidate, and potential business development. The board unanimously recommends shareholders vote in favor of both proposals.
Key Highlights
- Silexion Therapeutics to hold extraordinary general meeting on July 13, 2026.
- Shareholders to vote on approval of exercisability of New Warrants and Placement Agent Warrants.
- Proposal to increase authorized share capital by 10,000,000 ordinary shares.
- Meeting aims to maintain Nasdaq listing compliance ($2.5M shareholder equity requirement).
- Warrant Inducement Transaction raised approx. $1.0M to restore Nasdaq compliance.
- Proposed share capital increase needed for operations, clinical trials, and business development.
- Board unanimously recommends voting FOR both proposals.
Price Impact
More from SLXN